New combo therapy aims to tame melanoma treatment side effects

NCT ID NCT05428007

Recruiting now Disease control Sponsor: NYU Langone Health Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding the drug sarilumab to a standard immunotherapy combination can reduce severe side effects and work better for people with advanced melanoma that cannot be removed by surgery. About 105 participants will receive sarilumab along with ipilimumab, nivolumab, and relatlimab. The goal is to see if this approach is safer and more effective than current treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

melanoma metastatic melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MELANOMA UNRESECTABLE MELANOMA

Contacts and locations

Locations

Dana Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States
Massachusetts General Hospital
RECRUITING

Boston, Massachusetts, 02114, United States
NYU Langone Health
RECRUITING

New York, New York, 10016, United States
The Angeles Clinic at Cedars Sinai
RECRUITING

Los Angeles, California, 90025, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.